var data={"title":"Hyoscyamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hyoscyamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6347?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hyoscyamine-drug-information\" class=\"drug drug_general\">see &quot;Hyoscyamine: Drug information&quot;</a> and <a href=\"topic.htm?path=hyoscyamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hyoscyamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181212\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Anaspaz;</li>\n      <li>Ed-Spaz;</li>\n      <li>HyoMax-SL [DSC];</li>\n      <li>Hyosyne;</li>\n      <li>Levbid;</li>\n      <li>Levsin;</li>\n      <li>Levsin/SL;</li>\n      <li>NuLev;</li>\n      <li>Oscimin;</li>\n      <li>Oscimin SR;</li>\n      <li>Symax Duotab;</li>\n      <li>Symax FasTabs [DSC];</li>\n      <li>Symax-SL;</li>\n      <li>Symax-SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181213\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Levsin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059345\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticholinergic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antispasmodic Agent, Gastrointestinal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059339\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hyoscyamine-drug-information\" class=\"drug drug_general\">see &quot;Hyoscyamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Oral dosage forms (drops and elixirs) are different (ie, 0.125 mg/mL [drops] and 0.125 mg/5 mL [solution]); precaution should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented with corresponding product formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastrointestinal and urinary systemic spasms (including infant colic, biliary and renal colic):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years: Oral: Drops (eg, Hyosyne [0.125 mg/<b>mL</b>]): Do not exceed 6 doses in 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3.4 to &lt;5 kg: 0.01375 mg (0.11 mL or 4 <b>drops</b>) every 4 hours or as needed; maximum daily dose: 0.0825 mg (0.66 mL or 24 <b>drops</b>)/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">5 to &lt;7 kg: 0.0175 mg (0.14 mL or 5 <b>drops</b>) every 4 hours or as needed; maximum daily dose: 0.105 mg (0.84 mL or 30 <b>drops</b>)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">7 to &lt;10 kg: 0.02 mg (0.16 mL or 6 <b>drops</b>) every 4 hours or as needed; maximum daily dose: 0.12 mg (0.96 mL or 36 <b>drops</b>)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;10 kg: 0.0275 mg (0.22 mL or 8 <b>drops</b>) every 4 hours or as needed; maximum daily dose: 0.165 mg (1.32 mL or 48 <b>drops</b>)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;12 years: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Drops (eg, Hyosyne [0.125 mg/<b>mL</b>]): 0.03125 mg (0.25 mL) to 0.125 mg (1 mL) every 4 hours or as needed; maximum daily dose: 0.75 mg (6 mL)/<b>day</b>; do not exceed 6 doses in 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Elixir (eg, Hyosyne [0.125 mg/<b>5 mL</b>]): Do not exceed 6 doses in 24 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10 to &lt;20 kg: 0.03125 mg (1.25 mL) every 4 hours or as needed; maximum daily dose: 0.1875 mg (7.5 mL)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">20 to &lt;40 kg: 0.0625 mg (2.5 mL) every 4 hours or as needed; maximum daily dose: 0.375 mg (15 mL)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">40 to &lt;50 kg: 0.09375 mg (3.75 mL) every 4 hours or as needed; maximum daily dose: 0.5625 mg (22.5 mL)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;50 kg: 0.125 mg (5 mL) every 4 hours or as needed; maximum daily dose: 0.75 mg (30 mL)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablets, immediate release: regular tablet [Levsin], sublingual [Levsin/SL], dispersible [Anaspaz, ED-SPAZ, NuLev]): 0.0625 to 0.125 mg every 4 hours or as needed; maximum daily dose: 0.75 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Immediate release: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Drops (Hyosyne [0.125 mg/mL]): 0.125 mg (1 mL) to 0.25 mg (2 mL) every 4 hours or as needed; maximum daily dose: 1.5 mg (12 mL)/<b>da</b>y</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Elixir (Hyosyne [0.125 mg/<b>5 mL</b>]): 0.125 mg (5 mL) to 0.25 mg (10 mL) every 4 hours or as needed; maximum daily dose: 1.5 mg (60 mL)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Tablet, dispersible: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Anaspaz, ED-SPAZ, NuLev: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Oscimin: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Levsin: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Oscimin: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Tablet, sublingual </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Levsin/SL: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Oscimin, Symax SL: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Extended release:</i> Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Levbid: 0.375 to 0.75 mg every 12 hours; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oscimin SR, Symax Duotab, Symax SR: 0.375 to 0.75 mg every 12 hours or 0.375 mg every 8 hours; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preanesthesia:</b> Children &gt;2 years and Adolescents: IM, IV, SubQ: 5 <b>mcg</b>/kg administered  30 to 60 minutes prior to induction of anesthesia or at the time preoperative opioids or sedatives are administered </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reduce drug-induced bradycardia during surgery:</b> Children &gt;2 years and Adolescents: IV: 0.125 mg; repeat as needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of neuromuscular blockage:</b> Children &gt;2 years and Adolescents: IV, IM, SubQ: 0.2 mg for every 1 mg neostigmine (or physostigmine/pyridostigmine equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastrointestinal disorders: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablet, dispersible: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Anaspaz, ED-SPAZ, NuLev, Symax FasTab: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oscimin: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablet, extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Levbid: 0.375 to 0.75 mg every 12 hours; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oscimin SR, Symax Duotab, Symax SR: 0.375 to 0.75 mg every 12 hours <b>or</b> 0.375 mg every 8 hours; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablet, regular release:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Levsin: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oscimin: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablet, sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Levsin/SL: 0.125 to 0.25 mg every 4 hours or as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oscimin, Symax SL: 0.125 to 0.25 mg 3 to 4 times daily; may increase to every 4 hours as needed; maximum daily dose: 1.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Drops (Hyosyne [0.125 mg/<b>mL</b>]): 0.125 mg (1 mL) to 0.25 mg (2 mL) every 4 hours or as needed; maximum daily dose: 1.5 mg (12 mL)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Elixir (Hyosyne [0.125 mg/<b>5 mL</b>]): 0.125 mg (5 mL) to 0.25 mg (10 mL) every 4 hours or as needed; maximum daily dose: 1.5 mg (60 mL)/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV, SubQ: 0.25 to 0.5 mg; may repeat as needed up to 4 times daily, at 4-hour intervals </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnostic procedures:</b> IV: 0.25 to 0.5 mg given 5 to 10 minutes prior to procedure </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preanesthesia:</b> IM, IV, SubQ: 5 <b>mcg</b>/kg given 30 to 60 minutes prior to induction of anesthesia or at the time preoperative opioids or sedatives are administered </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reduce drug-induced bradycardia during surgery:</b> IV: 0.125 mg; repeat as needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reverse neuromuscular blockade:</b> IM, IV, SubQ: 0.2 mg for every 1 mg neostigmine (or the physostigmine/pyridostigmine equivalent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Dialyzable. There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181189\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Elixir, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hyosyne: 0.125 mg/5 mL (473 mL) [contains alcohol, usp; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.125 mg/5 mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levsin: 0.5 mg/mL (1 mL [DSC]) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levsin: 0.5 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hyosyne: 0.125 mg/mL (15 mL) [lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.125 mg/mL (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levsin: 0.125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oscimin: 0.125 mg [peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anaspaz: 0.125 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ed-Spaz: 0.125 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NuLev: 0.125 mg [peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oscimin: 0.125 mg [peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Symax FasTabs: 0.125 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Symax Duotab: 0.375 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levbid: 0.375 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oscimin SR: 0.375 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Symax-SR: 0.375 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.375 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HyoMax-SL: 0.125 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levsin/SL: 0.125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oscimin: 0.125 mg [peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Symax-SL: 0.125 mg [mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.125 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181175\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059348\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administration before meals (~30 to 60 minutes) is recommended but not required when used to treat gastrointestinal disorders. Additional product specific details: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Drops (Hyosyne): Use provided dropper to accurately measure dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, dispersible: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anaspaz: Tablets may be used sublingually, chewed, or swallowed whole</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ed-Spaz: Place on top of tongue and allow to dissolve; swallow with saliva</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">NuLev, Oscimin: Tablets may be chewed or placed on tongue and allowed to disintegrate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, extended release: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Levbid: Do not crush or chew</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oscimin SR, Symax Duotab, Symax SR: Swallow whole</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, sublingual: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Levsin/SL: Tablets may be used sublingually, chewed, or swallowed whole</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Symax SL: Tablets may be used sublingually or swallowed whole</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oscimin: Administer sublingually</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: May be administered undiluted IM, IV, and SubQ. There is no administration rate information provided in the manufacturer's labeling; some centers have administered over at least 1 minute.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181209\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059347\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Gastrointestinal:</i> Treatment of infant colic; aid in the control of acute episodes of gastric secretion, visceral spasm, hypermotility in spastic colitis, pylorospasm and associated abdominal cramps; relieve symptoms in functional intestinal disorders (eg, mild dysenteries, diverticulitis); adjunctive therapy for treatment of peptic ulcer, irritable bowel syndrome, other functional GI disorders, and neurogenic bowel disturbances; adjunctive therapy for symptomatic relief of biliary colic</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Urinary:</i> Aid in the control of hypermotility in spastic bladder and cystitis; adjunctive therapy in treatment of neurogenic bladder; adjunctive therapy for symptomatic relief of renal colic</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other:</i> Treatment of acute rhinitis as a &quot;drying agent&quot;; antidote for poisoning by anticholinesterase agents; management of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Approved ages and uses for products may vary; consult labeling for specific information.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Drops (eg, Hyosyne): FDA approved in pediatric patients weighing &ge;3.4 kg and adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Elixir (eg, Hyosyne): FDA approved in ages &ge;2 years and adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release tablets (eg, Levbid, Oscimin SR, Symax SR): FDA approved in ages &ge;12 years and adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release biphasic tablets (eg, Symax Duotab): FDA approved in ages &ge;12 years and adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Orally disintegrating tablet (eg, Anaspaz, ED-Spaz, NuLev): FDA approved in ages &ge;2 years and adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Orally disintegrating tablet (eg, Oscimin): FDA approved in ages &ge;12 years and adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral tablet (eg, Levsin): FDA approved in ages &ge;2 years and adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet (eg, Levsin SL): FDA approved in ages &ge;2 years and adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet (eg, Oscimin, Symax SL): FDA approved in ages &ge;12 years and adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Adjunct to anesthesia, reduction of drug-induced bradycardia during surgery, and reversal of neuromuscular blockade (FDA approved in ages &gt;2 years and adults); treatment of GI urinary tract disorders caused by spasm, biliary, and renal colic, antidote for poisoning by anticholinesterase agents, reduction of GI motility to facilitate diagnostic procedures and to improve radiologic visibility  of the kidneys, and reduction of pain and hypersecretion of pancreatitis (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181246\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Anaspaz may be confused with Anaprox, Antispas</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Levbid may be confused with Enbrel, Lithobid, Lopid, Lorabid</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Levsin/SL may be confused with Levaquin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Hyoscyamine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its highly anticholinergic properties and uncertain effectiveness as an antispasmodic (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181244\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing, palpitations, tachycardia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Amnesia (short-term), ataxia, confusion (more common in elderly), dizziness, drowsiness, excitement (more common in elderly), fatigue, hallucination, headache, insomnia, nervousness, psychosis, speech disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Hypohidrosis, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, ageusia, bloating, constipation, diarrhea, dysgeusia, dysphagia, heartburn, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Decreased lactation, impotence, urinary hesitancy, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, cycloplegia, increased intraocular pressure, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181195\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to belladonna alkaloids or any component of the formulation; glaucoma; obstructive uropathy (eg, bladder neck obstruction due to prostatic hypertrophy); myasthenia gravis; obstructive GI tract disease (eg, achalasia, pyloroduodenal stenosis), paralytic ileus, intestinal atony of elderly or debilitated patients, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis; unstable cardiovascular status; myocardial ischemia. <b>Note:</b> Some extended release products are not recommended in children &lt;12 years of age; refer to manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181179\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effect:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea: May be a sign of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy; treatment should be discontinued if this occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral effects: Prolonged use may lead to development of dental caries, periodontal disease, oral candidiasis, or discomfort due to decreased salivation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Has been reported in patients with an extreme sensitivity to anticholinergic effects; usually resolves within 12-48 hours after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, tachyarrhythmias, heart failure, or hypertension; evaluate tachycardia prior to administration. Use is contraindicated in patients with unstable cardiovascular status or myocardial ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hiatal hernia: Use with caution in patients with hiatal hernia with reflux esophagitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Use with caution in patients with autonomic neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia: Use with caution in patients with prostatic hyperplasia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in children with spastic paralysis or brain damage; may be more susceptible to anticholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46925831\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Large doses of anticholinergics may cause a paradoxical reaction in children characterized by hyperexcitability. Oral dosage forms (drops and elixirs) are different (ie, 0.125 mg/mL [drops] and 0.125 mg/5 mL [solution]); precaution should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented with corresponding product formulation. Hyosyne oral drops contain 5% v/v alcohol. Hyosyne oral elixir contains 20% v/v alcohol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299495\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181184\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13369&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Hyoscyamine. Management: Administer immediate release hyoscyamine before meals and antacids after meals when these agents are given in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181186\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181198\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Crosses the placenta, effects to the fetus not known; use during pregnancy only if clearly needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059344\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pulse, anticholinergic effects, urine output, GI symptoms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181178\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; increases cardiac output, dries secretions, antagonizes histamine and serotonin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181194\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 2 to 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Regular release: 4 to 6 hours; Extended release (Levbid, Symax Duotab): 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Regular release: 2 to 3.5 hours; Extended release (Levbid): ~7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181197\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Elixir</b> (Hyoscyamine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg/5 mL (473 mL): $104.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hyoscyamine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg/mL (15 mL): $39.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Levsin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/mL (1 mL): $71.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Hyoscyamine Sulfate Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (100): $58.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Levsin/SL Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (100): $286.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Symax-SL Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (100): $133.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Hyoscyamine Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 mg (100): $160.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Levbid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 mg (100): $489.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Symax-SR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 mg (100): $161.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Symax Duotab Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 mg (90): $247.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Anaspaz Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (100): $25.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Hyoscyamine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (100): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (NuLev Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (100): $225.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Hyoscyamine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (100): $84.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Levsin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (100): $286.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038655\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Buwecon (TW);</li>\n      <li>Duboisine (FR);</li>\n      <li>Egacene (NL);</li>\n      <li>Egazil Duretter (DK, FI, NO, SE);</li>\n      <li>Eyosin (PH);</li>\n      <li>Levsin (QA);</li>\n      <li>Levsin SL (HK);</li>\n      <li>Neo-Allospasmin (BG);</li>\n      <li>Nuspas (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyoscyamine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyoscyamine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anaspaz tablet (hyoscyamine) prescribing information]. Lenexa, KS: B.F. Ascher &amp; Company, Inc; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyoscyamine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ed-Spaz tablet (hyoscyamine) prescribing information]. Largo, FL: Belcher Pharmaceuticals, Inc; May 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hyosyne solution/drops (hyoscyamine) prescribing information]. Carmel, NY: Silarx Pharmaceuticals, Inc; June 2014. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levbid tablet  (hyoscyamine) prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levsin injection (hyoscyamine) prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; December 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levsin SL tablet (hyoscyamine) prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levsin tablet (hyoscyamine) prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nulev tablet (hyoscyamine) prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oscimin orally disintegrating tablets (hyoscyamine) prescribing information]. Canton, MS: Larken Laboratories Inc; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oscimin SL tablets (hyoscyamine) prescribing information]. Canton, MS: Larken Laboratories Inc; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oscimin SR tablets (hyoscyamine) prescribing information]. Canton, MS: Larken Laboratories Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oscimin tablets (hyoscyamine) prescribing information].  Canton, MS: Larken Laboratories Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Symtax Duotab tablets (hyoscyamine) prescribing information]. Ft. Worth, TX: Capellon Pharmaceuticals, LLC; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Symtax SL tablets (hyoscyamine) prescribing information]. Ft. Worth, TX: Capellon Pharmaceuticals, LLC; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Symtax SR tablet (hyoscyamine) prescribing information].  Ft. Worth, TX: Capellon Pharmaceuticals, LLC; May 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13369 Version 167.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181212\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181213\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059345\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059339\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181189\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F181175\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059348\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F181209\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059347\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F181246\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181244\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181195\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181179\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46925831\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299495\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181184\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F181186\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181198\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059344\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181178\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F181194\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F181197\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038655\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13369|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hyoscyamine-drug-information\" class=\"drug drug_general\">Hyoscyamine: Drug information</a></li><li><a href=\"topic.htm?path=hyoscyamine-patient-drug-information\" class=\"drug drug_patient\">Hyoscyamine: Patient drug information</a></li></ul></div></div>","javascript":null}